AVEO Oncology AVEO today announced that new clinical data on
its lead product candidate tivozanib, partnered with Astellas Pharma
Inc. (TSE: 4503), as well as its HGF inhibitory antibody ficlatuzumab
will be presented at the European Society of Medical Oncology (ESMO)
2012 Congress in Vienna, Austria, September 28 – October 2, 2012.
“At this year's ESMO, investigators will present new data on both our
lead product candidate tivozanib and our HGF inhibitory antibody
ficlatuzumab,” said William Slichenmyer, M.D., Sc.M., chief medical
officer, AVEO Oncology. “We believe the additional TIVO-1 analyses
underscore the safety profile of tivozanib in RCC while the new
ficlatuzumab data demonstrate its targeted inhibition of the HGF ligand.
We look forward to
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in